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ABSTRACT
DrugBank (http://www.drugbank.ca) is a richly
annotated database of drug and drug target infor-
mation. It contains extensive data on the nomencla-
ture, ontology, chemistry, structure, function,
action, pharmacology, pharmacokinetics, metabol-
ism and pharmaceutical properties of both small
molecule and large molecule (biotech) drugs. It
also contains comprehensive information on the
target diseases, proteins, genes and organisms on
which these drugs act. First released in 2006,
DrugBank has become widely used by pharmacists,
medicinal chemists, pharmaceutical researchers,
clinicians, educators and the general public. Since
its last update in 2008, DrugBank has been greatly
expanded through the addition of new drugs, new
targets and the inclusion of more than 40 new data
fields per drug entry (a 40% increase in data ‘depth’).
These data field additions include illustrated
drug-action pathways, drug transporter data, drug
metabolite data, pharmacogenomic data, adverse
drug response data, ADMET data, pharmacokinetic
data, computed property data and chemical classi-
fication data. DrugBank 3.0 also offers expanded
database links, improved search tools for drug–
drug and food–drug interaction, new resources for
querying and viewing drug pathways and hundreds
of new drug entries with detailed patent, pricing and
manufacturer data. These additions have been com-
plemented by enhancements to the quality and
quantity of existing data, particularly with regard to
drug target, drug description and drug action data.
DrugBank 3.0 represents the result of 2 years
of manual annotation work aimed at making
the database much more useful for a wide
range of ‘omics’ (i.e. pharmacogenomic,
pharmacoproteomic, pharmacometabolomic and
even pharmacoeconomic) applications.
INTRODUCTION
Historically most of the known information on drugs,
drug targets and drug action has resided in books,
journals and expensive commercial databases. Over the
past 5 years this situation has changed quite dramatically.
Now most drug and drug target data is freely available
over the internet. The ﬁrst on-line database to break the
commercial ‘stranglehold’ on drug information was the
Therapeutic Target Database (TTD), which was released
in 2002 and then updated in 2010 (1). Over the years, other
drug-speciﬁc databases have emerged, including PDTD
(2), STITCH (3), SuperTarget (4) and the Druggable
Genome database (5). These databases provide synoptic
data on drugs and their primary or putative drug targets.
Since the appearance of these drug/drug–target databases,
other kinds of drug resources have emerged including
PharmGKB (6), which specializes in pharmacogenetic
and pharmacogenomic data, RxList (www.rxlist.com)
and DailyMed (7), which provide electronic versions of
the FDA’s drug-product data sheets, ChEMBL (www.
ebi.ac.uk/chembl) which provides data on drug-like com-
pounds and BindingDB (8), which contains quantitative
drug-binding constant data. The growing appetite for
web-accessible drug data has also led PubChem (7),
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and drug information to their usual offerings. All of these
databases are outstanding resources, but as a general rule,
most of them are quite ‘lightly’ annotated with only 10–15
data ﬁelds per drug entry.
In contrast to most other open-access drug databases,
DrugBank (12) is a ‘richly’ annotated resource. The ﬁrst
version of DrugBank (released in 2006) contained nearly
90 data ﬁelds per drug entry, with detailed information on
the nomenclature, ontology, chemistry, structure,
function, action, pharmacology, pharmacokinetics, me-
tabolism and pharmaceutical properties of both drugs
and drug targets. Much of this data was acquired
through primary literature sources, checked by experts,
edited and entered manually. The richness, uniqueness
and quality of the data in DrugBank has clearly hit a
nerve with the research community. It is widely cited
(more than 400 citations), integrated into many interna-
tional databases (more than 20) and heavily used
(more than 4 million page visits/year) by pharmacists,
physicians, researchers, educators and the general public.
In an effort to keep up with the growing applications
and far-ranging requests for this particular database, an
updated version (DrugBank 2.0) was released in 2008 (13).
Since then, the amount of easily accessible or predictable
knowledge on drugs has grown considerably. So too has
the number of requests, suggested improvements and calls
for additional kinds of data to appear in DrugBank. Based
on this user feedback we have spent the past 2 years
enhancing both the quantity and quality of DrugBank’s
content. We have also added to or improved upon a
number of DrugBank’s querying and search functions.
The net result is a 40% increase in the number of data
ﬁelds for each drug entry, a considerable expansion
(>50%) in the number of drug–protein and food–drug
interactions, a massive increase in the information on
drug metabolites, drug ADMET (absorption, distribution,
metabolism, excretion, toxicology) data and the addition
of hundreds of colorful, interactive, hand-drawn drug-
action pathway diagrams. With these enhancements, we
believe DrugBank has become a much more comprehen-
sive and accessible drug information resource. It has also
become signiﬁcantly more useful for a wide range of
‘omics’ (i.e. pharmacogenomic, pharmacoproteomic,
pharmacometabolomic, pharmacoeconomic) applications.
A more detailed description of DrugBank 3.0 follows.
WHAT’S NEW IN DRUGBANK 3.0?
Details relating to DrugBank’s overall design, general
querying capabilities, curation protocols, structure depic-
tion conventions, quality assurance and drug selection
criteria have been described previously (12,13). These
have largely remained the same between release 2.0 and
3.0. Here, we shall focus primarily on describing the
changes and enhancements made to the database and to
the annotation processes for release 3.0. More speciﬁcally,
we will describe the: (i) growth and enhancements to
DrugBank’s existing content and quality; (ii) new data
ﬁeld additions; (iii) expanded database linkages and
(iv) enhanced data querying and viewing capabilities.
GROWTH AND ENHANCEMENT OF EXISTING
DATA
DrugBank has grown signiﬁcantly in the past 5 years with
perhaps the most signiﬁcant changes happening between
release 2.0 and 3.0. This progressive data content expan-
sion is summarized in Table 1. As can be seen from this
table, going from version 2.0 to 3.0, there has been a 40%
increase in the number of data ﬁelds for each drug entry.
Likewise there has been a 130% increase in the number of
computed structure parameters, an 80% increase in the
number of external database links, a 67% increase in
the number of experimental drugs, a 46% increase in the
number of food–drug interactions, a 42% increase in
the total number of drug targets, a 20% increase in the
number of possible DrugBank queries, a 13% increase in
the number of FDA-approved drug targets, a 12%
increase in the number of biotech and nutraceutical
drugs and a 6% increase in the number of FDA-
approved small molecule drugs.
In addition to signiﬁcantly expanding the data content
in DrugBank, a major effort has been directed at improv-
ing the quality of DrugBank’s existing data. Hundreds of
drug descriptions, mechanisms of action and pharmaco-
logical summaries have been either re-written or
expanded. Likewise, hundreds of new drug and drug–
target references were collected, checked and added.
Similarly, extensive checks have been performed on all
of DrugBank’s small molecule structures to conﬁrm that
they exhibit the correct chirality and stereochemistry. In
particular, we developed a custom structure-checking
program that used direct structure comparison (via a
Mol ﬁle) of each of DrugBank’s structures against the
corresponding structures in other databases (PubChem,
ChEBI, ChemSpider, etc.). Any DrugBank structure that
did not match with the corresponding structure in one or
more of these external databases was ﬂagged. A total of
340 structures were identiﬁed with potential structural
errors or discrepancies. Each of these was assessed and/
or corrected manually by a team of trained chemists. In
many cases the DrugBank structure was correct and the
external database structure was found to be in error, in
other cases the DrugBank structure was determined to be
in error and was subsequently corrected.
In addition to completing extensive data integrity
checks for all of DrugBank’s chemical data, the drug
target information in DrugBank 3.0 has been signiﬁcantly
improved. Now most of DrugBank’s approved-drug
targets are prioritized by relevance, with each target
being classiﬁed by its primary mode of action. One
mode-of-action category lists targets known to confer
the desired pharmacological effects, while the other lists
targets with unknown or unintended pharmacological
effects (many of which account for side effects). In
addition to our implementation of an improved target
classiﬁcation scheme, DrugBank 3.0 now formally separ-
ates drug-action targets from drug transporters, drug
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DrugBank, carriers are considered separate from trans-
porters as carriers move drugs around the body, while
transporters move drugs into and around the cell. This
kind of target separation should make drug-target
studies somewhat easier and substantially more
informative.
While many visible ‘front-end’ enhancements have been
implemented, DrugBank’s back-end has also been signiﬁ-
cantly enhanced. In particular, all of DrugBank’s data has
been converted to an easily parsed XML format. This
should make data downloads and the development of
data extraction routines much simpler and far faster for
programmers and database developers.
NEW DATA FIELD ADDITIONS
Each new release of DrugBank has been characterized by
a signiﬁcant increase in the number of new data ﬁelds
compared to the previous release. DrugBank 3.0 is no
exception. Going from version 2.0 to 3.0, there has been
a substantial increase in the number of data ﬁelds (going
from 108 to 148). Many of these data ﬁeld additions were
the results of speciﬁc requests by DrugBank users or arose
through consultation with members of the pharmaceutical
research community. DrugBank 3.0 now includes drug
pathway diagrams, drug transporter information, drug
carrier information, drug metabolite data, drug
metabolizing enzyme data, QSAR data, chemical classiﬁ-
cation data, SNP-associated drug effects (available
through the GenoBrowse link) and drug patent/pricing/
manufacturer data. Table 2 provides a more complete
listing of the new data ﬁelds appearing in DrugBank 3.0.
The ﬁve areas where most of the new data has been added
relate to: (i) pharmacometabolomics; (ii)
pharmacoproteomics; (iii) pharmacogenomics; (iv)
pharmacoeconomics and (v) computed structure
features. These additions are detailed below:
Pharmacometabolomics
As the ﬁeld of metabolomics has grown, so too has the
interest in understanding drug metabolism and in
characterizing drug metabolites. Indeed, it is now
recognized that drug metabolites play an important role
in understanding adverse drug effects, in determining
therapeutic indices and in leading to secondary or
off-target therapeutic effects. In an effort to make this
kind of metabolic or metabolomic information readily
available we have manually compiled detailed phase I/II
metabolic fate data for over 760 FDA-approved drugs.
The data, which was compiled from hundreds of journal
articles, includes links to pathways, chemical structures,
HMDB (14) entries, reaction parameters such as
reaction type (inducer, inhibitor and substrate), Km, and
Vmax, and reaction class information for nearly 720 drugs.
In addition to these annotations and molecular descriptors
for drug metabolism and drug metabolites, DrugBank 3.0
also provides classical ADMET information including
drug distribution, clearance and route of elimination
data. These new ‘metabolic’ data ﬁelds, when combined
with the structural and biological information already
stored in DrugBank, should offer an entirely new way of
exploiting the data in DrugBank.
Table 1. Comparison between the coverage in DrugBank 1.0, 2.0 and DrugBank 3.0
Category 1.0 2.0 3.0
No. of data ﬁelds 88 108 148
No. of search types 8 12 16
No. of drug-action pathways 0 0 223
No. of drugs with metabolizing enzyme data 0 0 762
No. of drug metabolites 0 0 811
No. of drugs with drug transporter data 0 0 516
No. of SNP-associated drug effects 0 0 113
No. of drugs with patent/pricing/manufacturer data 0 0 1208
No. of food–drug interactions 0 714 1039
No. of drug–drug interactions 0 13242 13795
No. of ADMET parameters (Caco-2, LogS) 0 276 890
No. of QSAR parameters per drug 5 6 14
No. of FDA-approved small molecule drugs 841 1344 1424
No. of biotech drugs 113 123 132
No. of nutraceutical drugs 61 69 82
No. of withdrawn drugs 0 57 68
No. of illicit drugs 0 188 189
No. of experimental drugs 2894 3116 5210
Total No. of experimental and FDA small molecule drugs 3796 4774 6684
Total No. of experimental and FDA drugs 3909 4897 6816
No. of names/brands/synonyms 18304 28447 37171
No. of approved-drug drug targets (unique) 524 1565 1768
No. of all drug targets (unique) 2133 3037 4326
No. of approved-drug enzymes/carriers (unique) 0 0 164
No. of all drug enzymes/carriers (unique) 0 0 169
No. of external database links 12 18 31
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It is often said that a picture is worth a thousand words. In
order to simplify DrugBank’s vast collection proteomic
data, DrugBank 3.0 now includes nearly 230 richly
illustrated drug-action pathways. These pathways have
been designed to display the action of drugs on protein
targets or protein receptors. Using the visualization frame-
work developed for SMPDB (15), each DrugBank
pathway is ‘image-mapped’, with every drug structure
being hyperlinked to the detailed descriptions contained
in DrugBank or HMDB and every protein or enzyme
complex being hyperlinked to the detailed descriptions
provided by UniProt (16). DrugBank’s drug-action
pathways are carefully hand-drawn and frequently
include information on the relevant organs, organelles,
subcellular compartments, protein targets, protein loca-
tions and drug structures that describe the pharmacology
or mode of action for that drug. All of DrugBank’s
pathways images may be progressively expanded by
clicking on the Zoom button located at the top and
bottom of the image or the magnifying-glass icons in the
Highlight/Analyzer box on the right of the image. At the
top of each image is a pathway synopsis while at the
bottom of each image is a list of relevant references.
Over the coming 2–3 years it is expected that another
1000–1200 drug pathways will be added to DrugBank’s
pathway inventory.
Pharmacogenomics
The relationship between drugs, genes and genetic variants
(SNPs) is central to the whole ﬁeld of pharmacogenomics
and personalized medicine. In an effort to address these
rapidly growing needs, DrugBank 3.0 now contains a sig-
niﬁcant amount of new pharmacogenomic information,
including data on 26292 coding (exon) SNPs and 73328
non-coding (intron) SNPs derived from known drug
targets. It also has data on 1188 coding SNPs and 8931
non-coding SNPs from known drug metabolizing
enzymes. SNP information can be accessed by clicking
on the ‘Show SNPs’ hyperlink listed beside either the
metabolizing enzymes or the drug target SNP ﬁeld.
These SNP summary tables include: (i) the reference
SNP ID, with a hyperlink to dbSNP (17); (ii) the allele
variants; (iii) the validation status; (iv) the chromosome
location and reference base position; (v) the functional
class (synonymous, non-synonymous, untranslated,
intron, exon); (vi) mRNA and protein accession links (if
applicable); (vii) the reading frame (if applicable); (viii) the
amino acid change (if existent); (ix) the allele frequency as
measured in African, European and Asian populations (if
available) and (x) the sequence of the gene fragment with
the SNP highlighted in a red box. The purpose of these
SNP tables is to allow DrugBank users to go directly from
a drug of interest to a list of potential SNPs that may
contribute to the reaction or response seen in a given
patient or in a given population.
In addition to this drug target SNP data, Drugbank 3.0
now includes two tables that provide much more explicit
information on the relationship between drug responses/
reactions and gene variant or SNP data. These tables,
which are accessible from the GenoBrowse submenu
located on DrugBank’s Browse menu bar, are called
SNP-FX (short for SNP-associated effects) and
SNP-ADR (short for SNP-associated adverse drug reac-
tions). SNP-FX contains data on the drug, the interacting
protein(s), the ‘causal’ SNPs or genetic variants for that
gene/protein, the therapeutic response or effects caused by
the SNP-drug interaction (improved or diminished
response, changed dosing requirements, etc.) and the
associated references describing these effects in more
detail. SNP-ADR follows a similar format to SNP-FX
but the clinical responses are restricted only to adverse
drug reactions (ADR). SNP-FX contains
literature-derived data on the therapeutic effects or thera-
peutic responses for more than 60 drug-polymorphism
combinations, while SNP-ADR contains data on adverse
reactions compiled from more than 50
drug-polymorphsim pairings. All of the data in these
tables is hyperlinked to drug entries from DrugBank,
protein data from UniProt, SNP data from dbSNP and
bibliographic data from PubMed.
Pharmacoeconomics
Perhaps the most important ‘omics’ discipline in the
pharmaceutical world is econ-‘omics’. Indeed, the selec-
tion of disease targets, the money spent on research and
the money recovered from sales are largely determined by
economic factors. To facilitate research into these issues
DrugBank 3.0 has added data on drug patent dates (from
Canada and the United States), drug manufacturers, drug
packagers, drug prices (from different jurisdictions) and
drug sales (where available). Coupled with other data
already in DrugBank (such as ATC codes, indications,
side effects, structures, chemical classes) this information
should enable more detailed studies on the relationship
between drug prices and patent dates, the connection
Table 2. New data ﬁelds in DrugBank 3.0
Chemical kingdom ChEMBL link
Chemical class Drug pathway
Chemical substructures Drug pathway SMPDB ID
Drug manufacturers Target actions (antagonist, agonist)
Drug packagers Target priority
Drug prices Target pharmacological effect
(known/unknown/none)
Original patent date Enzyme actions (inhibitor, inducer, substrate)
Original patent number Drug metabolite structure
Last patent expiry date Drug metabolite name
Last patent number Drug metabolite HMDB ID
MMCD link Drug metabolite reaction type (e.g. oxidation)
ChemSpider ID and
link
Reaction Km value
NDC ID and link Reaction Vmax value
DailyMed link Metabolizing enzyme references
Drugs.com link Metabolizing enzyme priority
OMIM link Drug transporter name
CDPD link Drug transporter actions (substrate,
inhibitor, inducer)
TTD link Route of elimination
STITCH link Volume of distribution
BindingDB link Clearance
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between drug sales and disease targets, the link between
a drug’s price and the drug’s side effects as well as the
relationship between drug manufacturers and disease
target choices. It should also enable research into histor-
ical trends in drug target or disease target choices as well
as long-term trends in the use or exploitation of certain
drug motifs or structure classes (e.g. statins, tricyclic
drugs).
Computed structure data
Computed structure parameters or descriptors are fre-
quently used in quantitative structure activity
relationship (QSAR) studies to facilitate rational drug
design, drug screening and medicinal chemistry. These
computed structure parameters may also be used to ra-
tionalize drug activities, tissue localization, adverse reac-
tions and drug metabolism. While earlier versions of
DrugBank had provided a nominal number of computed
structure descriptors (molecular weight, pKa, LogP,
LogS), these were often not sufﬁcient for detailed feature
analyses or comprehensive in silico comparisons.
DrugBank 3.0 now provides an additional set of nine
computed property descriptors including (i) the number
of H-bond acceptors; (ii) the number of H-bond donors;
(iii) the number of freely rotating bonds; (iv) the index of
refraction; (v) the predicted boiling/melting point; (vi) the
polar surface area; (vii) the molar refractivity; (viii) the
polarizability and (ix) the molecular density. These
properties are displayed in a summary table with links
to the SDF ﬁle containing these values. While more
computed structure descriptors are certainly available,
these represent the most frequently used descriptors and
should allow DrugBank users to perform much more
detailed computed structure queries, analyses and
comparisons.
EXPANDED DATABASE LINKAGES
Because DrugBank was designed to cover a broad
spectrum of scientiﬁc disciplines it has always been exten-
sively linked to many external databases. For instance,
version 2.0 of DrugBank contained up to 18 database
hyperlinks in every DrugCard entry, including links to
KEGG (9), PubChem (7), ChEBI (10), PharmGKB (6),
PDB (18), GenBank (19), DIN, RxList, PDRhealth,
Wikipedia, ATC, UniProt (16), Pfam (20), dbSNP (17),
GeneCards (21), GenAtlas (22), HGNC and PubMed.
DrugBank 3.0 now contains an average of 31 hyperlinks
per DrugCard. These new links include numerous
compound-speciﬁc, spectral, pathway and disease data-
bases such as ChemSpider (11), HMDB (14), MMCD
(23), SMPDB (15) and OMIM (24). We have also added
new links to several dedicated drug and pharmaceutical
databases [DailyMed (7), Drugs.com, the National Drug
Code identiﬁer database and the Canadian Drug Product
Database] as well as a number of drug target databases,
such as the Therapeutic Target Database (TTD), STITCH
(4), BindingDB (8) and ChEMBL. These DrugCard
hyperlinks are also complemented with a comprehensive
list of links in the ‘About’ section of DrugBank. In
addition to these external database links, DrugBank has
been reciprocally linked to several major resources
including Wikipedia, UniProt (16), BioMOBY (25),
PubChem (7), KEGG (9), PharmGKB (6), Drugs.com
and ChemSpider (11).
ENHANCED QUERYING AND VIEWING
CAPABILITIES
One of the key strengths for DrugBank has been its
support for a wide range of querying and visualization
tools. These include 2D and 3D structure viewers,
ﬂexible text querying systems, structure searching/
matching, sequence searching tools, data extraction tools
and easy-to-use browsers. For DrugBank 3.0 we have
made a number of improvements to the existing query
tools but are also introducing four new browsing or
search tools. These include PathBrowse, GenoBrowse,
ClassBrowse, ReceptorBrowse and the Interax
Interaction Search (Figure 1). We believe all ﬁve should
make the viewing and retrieval of information in
DrugBank much easier.
PathBrowse was developed to facilitate the viewing and
searching of DrugBank’s drug-action pathways. Each
hyperlinked, interactive pathway explains the mode of
action of drugs at a molecular, cellular and/or physiologic-
al level. PathBrowse allows users to search for drugs by
DrugBank ID, name or synonyms. It also supports the
search for drug targets, metabolizing enzymes, carriers
and transporters either by their name, UniProt ID or
gene identiﬁer. The results are displayed as a highlighted
list of hits. Once a pathway is selected, users can inter-
actively explore the pathway image, with compound or
protein hits highlighted in the pathway image. This tight
integration between DrugBank and SMPDB should allow
researchers to visualize the ‘big picture’ with respect to
drugs and how they act or how they are processed in the
body. The two other browsing functions (ClassBrowse
and GenoBrowse) are somewhat simpler in design and
functionality than PathBrowse. ClassBrowse allows users
to search through or sort drugs by their chemical class or
chemical taxonomy while GenoBrowse (which has already
been described) allows users to browse through or explore
SNP-induced drug effects or drug reactions.
ReceptorBrowse allows users to search or sort through
the protein targets, enzymes, carriers and transporters
(along with their function and target species information)
that are associated with each drug in DrugBank.
DrugBank contains one of the most complete, freely
available sources of drug–drug and food–drug interaction
data on the Internet today. Although this information has
been made available in each DrugCard from version 2.0
onwards, the data has not been easily searchable. The
‘Interax’ Interaction Search was developed to allow
facile searching of drug and food interactions. Unlike
existing interaction search tools, Interax takes the
process one step further by including transporter, target
and enzyme information in the search results. Several dif-
ferent search types are supported by Interax. For instance,
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be performed, whereby a user inputs a list of drugs,
presses the ‘submit’ button and a list of drug and food
interactions are produced. Users can also input two lists
of drugs and Interax will identify any interactions between
the lists. Additionally, any interactions that may be target,
enzyme, carrier or transporter related (e.g. two drugs bind
the same target) will be ﬂagged with symbols representing
a target interaction, enzyme interaction, carrier interaction
or transporter interaction. This comprehensive search
functionality provides a unique method of searching and
exploring drug–drug interactions and should be of interest
to pharmacists, pharmaceutical researchers, and the
general public.
CONCLUSION
DrugBank 3.0 contains a signiﬁcant number of enhance-
ments over its predecessor (DrugBank 2.0). As highlighted
throughout this article, numerous improvements have
Figure 1. A screenshot montage of some of DrugBank 3.0’s new browser views (GenoBrowse, Interax, ClassBrowse, PathBrowse).
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tion of the information provided. These include the
addition of new drugs, new targets, new data ﬁelds, new
links and new tools. DrugBank 3.0 now contains
illustrated drug-action pathways, drug transporter data,
drug metabolite data, pharmacogenomic data, adverse
drug response data, ADMET data, pharmacokinetic
data, extensive computed property data and chemical clas-
siﬁcation data. DrugBank 3.0 also offers expanded
database links, improved search tools for drug–drug and
food–drug interaction, new tools for searching and
viewing drug pathways and hundreds of new drug
entries with detailed patent, pricing and manufacturer
data. These additions have been complemented by
enhancements to the quality and quantity of existing
data, particularly with regard to drug target, drug descrip-
tion and drug action data. With these enhancements
DrugBank 3.0 should be much more useful for a wider
range of ‘omics’ applications. It is hoped that with more
user feedback, DrugBank will continue to develop to ﬁt
the needs of its users and provide an increasingly useful,
information-rich drug resource.
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